¼¼°èÀÇ °£°æº¯ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ¿¹Ãø±â°£Áß ¼ºÀåÀº °£¿° °¨¿° Áõ°¡, °æÁ¦¼ºÀå »ó½Â, µµ½ÃÈ ÁøÀü, ¶óÀÌÇÁ½ºÅ¸ÀÏ º¯È, ÀÇ·á °ü±¤ÀÇ ¼ºÀå¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù.
¾ËÄÚ¿Ã ¼Òºñ·® Áõ°¡°¡ °£°æº¯ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °úµµÇÑ ¾ËÄÚ¿Ã ¼·Ãë°¡ Àִ ȯÀÚ¿¡ ´ëÇØ °£°æº¯ÀÇ Ä¡·á´Â ÁÖ·Î ±ÝÁÖ, ¾àÁ¦Ä¡·á, ÁöÁö¿ä¹ý¿¡ ÀÇÇÑ °£Àå¾ÖÀÇ °ü¸®¿¡ ÁßÁ¡À» µÎ°í, »ó´ã°ú ÀçȰÀ» ÅëÇØ ¾ËÄÚ¿Ã Áßµ¶¿¡ ´ëóÇÕ´Ï´Ù. 2023³â 3¿ù, National Drugs Library¿¡ µû¸£¸é 2022³â 15¼¼ ÀÌ»óÀÇ ¾ËÄÚ¿Ã ¼Òºñ·®Àº 1ÀÎ´ç Æò±Õ 10.2¸®ÅÍ·Î 2021³âº¸´Ù 7.6% Áõ°¡Çß½À´Ï´Ù.
°£°æº¯ ½ÃÀåÀÇ ±â¾÷Àº ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí Ä¡·á ¿É¼ÇÀ» ³ÐÈ÷±â À§ÇØ ´Éµ¿Çü ÀÓº£µðµå ÀÇ·á±â±â °³¹ß µî »õ·Î¿î Ä¡·áÀÇ Áøº¸¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. 2024³â 12¿ù, Sequana Medical NV´Â °£°æº¯À¸·Î ÀÎÇÑ Àç¹ß¼º ¶Ç´Â ³Ä¡¼º º¹¼ö¸¦ °ü¸®Çϱâ À§ÇØ ¹Ì±¹¿¡¼ ½ÂÀÎµÈ ÃÖÃÊÀÇ ´Éµ¿ À̽ÄÇü ÀÇ·á±â±âÀÎ alfapump ½Ã½ºÅÛÀÇ ¹Ì±¹ FDA ½ÂÀÎÀ» ÃëµæÇß½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ÁÖ¿ä ¿ä¾à
Á¦2Àå ½ÃÀå Æ¯Â¡
Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«
Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À
Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©
- ¼¼°èÀÇ °£°æº¯ PESTEL ºÐ¼®(Á¤Ä¡, »çȸ, ±â¼ú, ȯ°æ, ¹ýÀû ¿äÀÎ, ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ)
- ÃÖÁ¾ ÀÌ¿ë »ê¾÷ÀÇ ºÐ¼®
- ¼¼°èÀÇ °£°æº¯ ½ÃÀå : ¼ºÀå·ü ºÐ¼®
- ¼¼°èÀÇ °£°æº¯ ½ÃÀå ½ÇÀû : ±Ô¸ð¿Í ¼ºÀå, 2019-2024³â
- ¼¼°èÀÇ °£°æº¯ ½ÃÀå ¿¹Ãø : ±Ô¸ð¿Í ¼ºÀå, 2024-2029³â, 2034³â
- ¼¼°èÀÇ °£°æº¯ Àüü ½ÃÀå ±Ô¸ð(TAM)
Á¦6Àå ½ÃÀå ¼¼ºÐÈ
- ¼¼°èÀÇ °£°æº¯ ½ÃÀå : À¯Çüº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- ¾ËÄڿüº °£°æº¯
- À§Ã༺ °£°æº¯
- ´ãÁó¼º °£°æº¯
- ½ÉÀ强 °£°æº¯
- ¿øÀÎ ºÒ¸í °£°æº¯
- ¼¼°èÀÇ °£°æº¯ ½ÃÀå : Ä¡·áº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- Ç×»ýÁ¦
- ¸é¿ª¾ïÁ¦Á¦
- ±âŸ
- ¼¼°èÀÇ °£°æº¯ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- º´¿ø
- Àü¹® Ŭ¸®´Ð
- ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
- Çмú¿¬±¸±â°ü
- ±âŸ
- ¼¼°èÀÇ °£°æº¯ ½ÃÀå : ¾ËÄڿüº °£°æº¯º°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- º¸»ó¼º ¾ËÄڿüº °£°æº¯
- ºñ´ë»ó¼º ¾ËÄڿüº °£°æº¯
- ¾ËÄڿüº Áö¹æ°£¿°(ASH) °ü·Ã °£°æº¯
- ¼¼°èÀÇ °£°æº¯ ½ÃÀå : À§Ã༺ °£°æº¯º°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- ±«»ç ÈÄ À§Ã༺ °£°æº¯
- ´ë°áÀý¼º À§Ã༺ °£°æº¯
- ¼Ò°áÀý¼º À§Ã༺ °£°æº¯
- ¼¼°èÀÇ °£°æº¯ ½ÃÀå : ´ãÁó¼º °£°æº¯º°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- ¿ø¹ß¼º ´ãÁó¼º °£°æº¯(PBC)
- 2Â÷¼º ´ãÁó¼º °£°æº¯
- ÀÚ°¡¸é¿ª¼º ´ãÁó¼º °£°æº¯
- ¼¼°èÀÇ °£°æº¯ ½ÃÀå : ½ÉÀ强 °£°æº¯º°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- ¿ì½ÉºÎÀü À¯¹ß¼º °£°æº¯
- ¸¸¼º ¼öµ¿¼º ¿ïÇ÷¼º °£°æº¯
- ÇãÇ÷¼º °£¿° °£°æº¯
- ¼¼°èÀÇ °£°æº¯ ½ÃÀå : ¿øÀÎ ºÒ¸í °£°æº¯º°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- ºñ¾ËÄڿüº Áö¹æ°£¿°(NASH) °ü·Ã °£°æº¯
- Ư¹ß¼º °£°æº¯
- ´ë»ç ÁõÈıº °ü·Ã °£°æº¯
Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®
- ¼¼°èÀÇ °£°æº¯ ½ÃÀå : Áö¿ªº°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
- ¼¼°èÀÇ °£°æº¯ ½ÃÀå : ±¹°¡º°, ºÐ¼®°ú ¿¹Ãø, 2019-2024³â, 2024-2029³â, 2034³â
Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå
Á¦9Àå Áß±¹ ½ÃÀå
Á¦10Àå Àεµ ½ÃÀå
Á¦11Àå ÀϺ» ½ÃÀå
Á¦12Àå È£ÁÖ ½ÃÀå
Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå
Á¦14Àå Çѱ¹ ½ÃÀå
Á¦15Àå ¼À¯·´ ½ÃÀå
Á¦16Àå ¿µ±¹ ½ÃÀå
Á¦17Àå µ¶ÀÏ ½ÃÀå
Á¦18Àå ÇÁ¶û½º ½ÃÀå
Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå
Á¦20Àå ½ºÆäÀÎ ½ÃÀå
Á¦21Àå µ¿À¯·´ ½ÃÀå
Á¦22Àå ·¯½Ã¾Æ ½ÃÀå
Á¦23Àå ºÏ¹Ì ½ÃÀå
Á¦24Àå ¹Ì±¹ ½ÃÀå
Á¦25Àå ij³ª´Ù ½ÃÀå
Á¦26Àå ³²¹Ì ½ÃÀå
Á¦27Àå ºê¶óÁú ½ÃÀå
Á¦28Àå Áßµ¿ ½ÃÀå
Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå
Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ
- °£°æº¯ ½ÃÀå : °æÀï ±¸µµ
- °£°æº¯ ½ÃÀå : ±â¾÷ ÇÁ·ÎÆÄÀÏ
- Pfizer Inc.
- F. Hoffmann-La Roche AG
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- Abbott Laboratories
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Gilead Sciences Inc.
- Novo Nordisk A/S
- Viatris Inc.
- Grifols Therapeutics LLC
- Shionogi Inc.
- Galectin Therapeutics Inc.
- NGM Biopharmaceuticals Inc.
- Madrigal Pharmaceuticals Inc.
- Akero Therapeutics Inc.
Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå
Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)
Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ
Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«
- °£°æº¯ ½ÃÀå(2029³â) : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ±¹°¡
- °£°æº¯ ½ÃÀå(2029³â) : »õ·Î¿î ±âȸ¸¦ Á¦°øÇÏ´Â ºÎ¹®
- °£°æº¯ ½ÃÀå(2029³â) : ¼ºÀå Àü·«
- ½ÃÀå µ¿Çâ¿¡ ÀÇÇÑ Àü·«
- °æÀï Àü·«
Á¦36Àå ºÎ·Ï
JHS
Liver cirrhosis is a progressive condition where healthy liver tissue is gradually replaced by scar tissue, impairing the liver's ability to function effectively. This disease results from prolonged liver damage caused by factors such as chronic alcohol consumption, viral hepatitis, or fatty liver disease.
The main types of liver cirrhosis include alcoholic cirrhosis, atrophic cirrhosis, biliary cirrhosis, cardiac cirrhosis, and cryptogenic cirrhosis. Alcoholic cirrhosis is a severe form of liver disease caused by long-term excessive alcohol consumption, which leads to liver scarring, dysfunction, and potential liver failure. Various treatment options are available, including antibiotics, immunosuppressants, and other therapies. Key end users of these treatments include hospitals, specialty clinics, ambulatory surgical centers, academic and research institutes, among others.
The liver cirrhosis market research report is one of a series of new reports from The Business Research Company that provides liver cirrhosis market statistics, including the liver cirrhosis industry global market size, regional shares, competitors with the liver cirrhosis market share, detailed liver cirrhosis market segments, market trends, and opportunities, and any further data you may need to thrive in the liver cirrhosis industry. This liver cirrhosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The liver cirrhosis market size has grown rapidly in recent years. It will grow from $1.86 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be attributed to the rising prevalence of liver diseases, high alcohol consumption, an aging population, higher healthcare expenditure, and growing government initiatives.
The liver cirrhosis market size is expected to see rapid growth in the next few years. It will grow to $2.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth during the forecast period can be attributed to the increasing incidence of hepatitis infections, rising economic growth, greater urbanization, lifestyle changes, and the growth of medical tourism. Key trends during this period include advancements in diagnostic tools, technological innovations, collaborations and partnerships, the integration of artificial intelligence, and the incorporation of holistic therapies.
The rising consumption of alcohol is expected to drive the growth of the liver cirrhosis market. Alcohol consumption, typically measured by its quantity and frequency, is increasing as it helps people relax from daily stress, promotes social connections at gatherings, and enhances moments of relaxation. Additionally, alcohol is widely advertised through media and is more accessible in various settings. For patients with excessive alcohol consumption, liver cirrhosis treatment primarily focuses on managing liver damage through abstinence, medications, and supportive care, while addressing alcohol dependence through counseling and rehabilitation. For example, in March 2023, the National Drugs Library, an Ireland-based data collection organization, reported that in 2022, the average alcohol consumption among individuals aged 15 and older increased to 10.2 liters of pure alcohol per capita, reflecting a 7.6% rise from 2021. This increase in alcohol consumption is contributing to the growth of the liver cirrhosis market.
Companies in the liver cirrhosis market are focusing on new treatment advancements, such as the development of active implantable medical devices, to improve patient outcomes and expand treatment options. Active implantable medical devices are electronically powered implants designed to monitor, support, or improve organ function within the body. For example, in December 2024, Sequana Medical NV, a Belgium-based medical device company, received U.S. FDA approval for its alfapump system, the first active implantable medical device approved in the U.S. for managing recurrent or refractory ascites caused by liver cirrhosis. This breakthrough technology offers a continuous, automated solution for fluid management by transferring excess abdominal fluid to the bladder, significantly reducing the need for invasive paracentesis. The alfapump system represents a significant step forward in improving patient outcomes and quality of life, with an addressable market of around 70,000 patients in the U.S.
In September 2023, Galectin Therapeutics, a U.S.-based company specializing in liver cirrhosis treatment, partnered with HistoIndex to present their findings on liver cirrhosis at the 9th Paris NASH meeting. Through this collaboration, the two companies aim to utilize artificial intelligence to enhance the analysis of liver cirrhosis histology, providing deeper insights into disease progression and the effectiveness of treatments. HistoIndex is a Singapore-based company specializing in medical technology.
Major players in the liver cirrhosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Viatris Inc., Grifols Therapeutics LLC, Shionogi Inc., Galectin Therapeutics Inc., NGM Biopharmaceuticals Inc., Madrigal Pharmaceuticals Inc., Akero Therapeutics Inc.
North America was the largest region in the liver cirrhosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the liver cirrhosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The liver cirrhosis market consists of revenues earned by entities providing services such as diagnosis and screening services, medical treatment, management services, and patient support. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cirrhosis market also includes sales of medications, diagnostic tools, medical devices, and therapeutic treatments. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Liver Cirrhosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on liver cirrhosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for liver cirrhosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The liver cirrhosis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Alcoholic Cirrhosis; Atrophic Cirrhosis; Biliary Cirrhosis; Cardiac Cirrhosis; Cryptogenic Cirrhosis
- 2) By Treatment: Antibiotics; Immunosuppressants; Other Treatments
- 3) By End Users: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Academic And Research Institutes; Other End Users
- Sub Segments:
- 1) By Alcoholic Cirrhosis: Compensated Alcoholic Cirrhosis; Decompensated Alcoholic Cirrhosis; Alcoholic Steatohepatitis (ASH)-Associated Cirrhosis
- 2) By Atrophic Cirrhosis: Post-necrotic Atrophic Cirrhosis; Macronodular Atrophic Cirrhosis; Micronodular Atrophic Cirrhosis
- 3) By Biliary Cirrhosis: Primary Biliary Cirrhosis (PBC); Secondary Biliary Cirrhosis; Autoimmune Biliary Cirrhosis
- 4) By Cardiac Cirrhosis: Right Heart Failure-Induced Cirrhosis; Chronic Passive Congestion Cirrhosis; Ischemic Hepatitis Cirrhosis
- 5) By Cryptogenic Cirrhosis: Non-Alcoholic Steatohepatitis (NASH)-Associated Cirrhosis; Idiopathic Cirrhosis; Metabolic Syndrome-Associated Cirrhosis
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Liver Cirrhosis Market Characteristics
3. Liver Cirrhosis Market Trends And Strategies
4. Liver Cirrhosis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Liver Cirrhosis Growth Analysis And Strategic Analysis Framework
- 5.1. Global Liver Cirrhosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Liver Cirrhosis Market Growth Rate Analysis
- 5.4. Global Liver Cirrhosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Liver Cirrhosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Liver Cirrhosis Total Addressable Market (TAM)
6. Liver Cirrhosis Market Segmentation
- 6.1. Global Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Alcoholic Cirrhosis
- Atrophic Cirrhosis
- Biliary Cirrhosis
- Cardiac Cirrhosis
- Cryptogenic Cirrhosis
- 6.2. Global Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antibiotics
- Immunosuppressants
- Other Treatments
- 6.3. Global Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Academic And Research Institutes
- Other End Users
- 6.4. Global Liver Cirrhosis Market, Sub-Segmentation Of Alcoholic Cirrhosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Compensated Alcoholic Cirrhosis
- Decompensated Alcoholic Cirrhosis
- Alcoholic Steatohepatitis (ASH)-Associated Cirrhosis
- 6.5. Global Liver Cirrhosis Market, Sub-Segmentation Of Atrophic Cirrhosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Post-necrotic Atrophic Cirrhosis
- Macronodular Atrophic Cirrhosis
- Micronodular Atrophic Cirrhosis
- 6.6. Global Liver Cirrhosis Market, Sub-Segmentation Of Biliary Cirrhosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Primary Biliary Cirrhosis (PBC)
- Secondary Biliary Cirrhosis
- Autoimmune Biliary Cirrhosis
- 6.7. Global Liver Cirrhosis Market, Sub-Segmentation Of Cardiac Cirrhosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Right Heart Failure-Induced Cirrhosis
- Chronic Passive Congestion Cirrhosis
- Ischemic Hepatitis Cirrhosis
- 6.8. Global Liver Cirrhosis Market, Sub-Segmentation Of Cryptogenic Cirrhosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Non-Alcoholic Steatohepatitis (NASH)-Associated Cirrhosis
- Idiopathic Cirrhosis
- Metabolic Syndrome-Associated Cirrhosis
7. Liver Cirrhosis Market Regional And Country Analysis
- 7.1. Global Liver Cirrhosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Liver Cirrhosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Liver Cirrhosis Market
- 8.1. Asia-Pacific Liver Cirrhosis Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Liver Cirrhosis Market
- 9.1. China Liver Cirrhosis Market Overview
- 9.2. China Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Liver Cirrhosis Market
- 10.1. India Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Liver Cirrhosis Market
- 11.1. Japan Liver Cirrhosis Market Overview
- 11.2. Japan Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Liver Cirrhosis Market
- 12.1. Australia Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Liver Cirrhosis Market
- 13.1. Indonesia Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Liver Cirrhosis Market
- 14.1. South Korea Liver Cirrhosis Market Overview
- 14.2. South Korea Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Liver Cirrhosis Market
- 15.1. Western Europe Liver Cirrhosis Market Overview
- 15.2. Western Europe Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Liver Cirrhosis Market
- 16.1. UK Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Liver Cirrhosis Market
- 17.1. Germany Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Liver Cirrhosis Market
- 18.1. France Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Liver Cirrhosis Market
- 19.1. Italy Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Liver Cirrhosis Market
- 20.1. Spain Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Liver Cirrhosis Market
- 21.1. Eastern Europe Liver Cirrhosis Market Overview
- 21.2. Eastern Europe Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Liver Cirrhosis Market
- 22.1. Russia Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Liver Cirrhosis Market
- 23.1. North America Liver Cirrhosis Market Overview
- 23.2. North America Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Liver Cirrhosis Market
- 24.1. USA Liver Cirrhosis Market Overview
- 24.2. USA Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Liver Cirrhosis Market
- 25.1. Canada Liver Cirrhosis Market Overview
- 25.2. Canada Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Liver Cirrhosis Market
- 26.1. South America Liver Cirrhosis Market Overview
- 26.2. South America Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Liver Cirrhosis Market
- 27.1. Brazil Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Liver Cirrhosis Market
- 28.1. Middle East Liver Cirrhosis Market Overview
- 28.2. Middle East Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Liver Cirrhosis Market
- 29.1. Africa Liver Cirrhosis Market Overview
- 29.2. Africa Liver Cirrhosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Liver Cirrhosis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Liver Cirrhosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Liver Cirrhosis Market Competitive Landscape And Company Profiles
- 30.1. Liver Cirrhosis Market Competitive Landscape
- 30.2. Liver Cirrhosis Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Liver Cirrhosis Market Other Major And Innovative Companies
- 31.1. Bristol-Myers Squibb Company
- 31.2. AstraZeneca PLC
- 31.3. Abbott Laboratories
- 31.4. Novartis AG
- 31.5. Takeda Pharmaceutical Company Limited
- 31.6. Eli Lilly and Company
- 31.7. Gilead Sciences Inc.
- 31.8. Novo Nordisk A/S
- 31.9. Viatris Inc.
- 31.10. Grifols Therapeutics LLC
- 31.11. Shionogi Inc.
- 31.12. Galectin Therapeutics Inc.
- 31.13. NGM Biopharmaceuticals Inc.
- 31.14. Madrigal Pharmaceuticals Inc.
- 31.15. Akero Therapeutics Inc.
32. Global Liver Cirrhosis Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Liver Cirrhosis Market
34. Recent Developments In The Liver Cirrhosis Market
35. Liver Cirrhosis Market High Potential Countries, Segments and Strategies
- 35.1 Liver Cirrhosis Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Liver Cirrhosis Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Liver Cirrhosis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer